Argenica Therapeutics (ASX:AGN)
ASX announcement history & article coverage
Transparent by design.
Announcments by Argenica Therapeutics (ASX:AGN) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Appendix 4G & Corporate Governance Statement
Appendix 4E & Annual Report to 30 June 2026
Argenica Therapeutics reports improved FY2026 results and advances stroke drug development
Notification of cessation of securities - AGN
Investor Presentation - Techknow Conference
Quarterly Activities/Appendix 4C Cash Flow Report
Argenica advances late-stage stroke trial preparations with strong safety data and $6.35M cash reserves
ARG007 Shows Significant Neuroprotection in Concussion Study
ARG-007 shows significant neuroprotection in preclinical concussion study
Investor Webinar
Investor Presentation
ARG007 (Xaranetide) Completes All Three FDA Requested Assays
Argenica completes final FDA safety assay for ARG-007, advancing clinical trial plans
WHO Confirms Xaranetide as INN for ARG-007
WHO Confirms Xaranetide as INN for Argenica's ARG-007